I am a passionate scientist working in life science and cancer early molecular diagnosis, an active reviewer for Journal Frontiers, Scientific Reports, Molecular Therapy, etc., and a volunteer as the commentator providing weekly News Watch on cancer research for Canada Cancer Research Society.KEY QUALIFICATION• 20+ peer-reviewed articles on journals, such as JAMA Network Open, EBioMedicine, Oncogene, Oncotarget, Hypertension, JCS, JCEM, et.al;• 10+ years’ experience in running molecular & cellular biomedical laboratory, and training & supervising students and junior researchers;• 5+ years’ experience in clinical laboratory biosafety management achieving Public Health Agency of Canada (PHAC) Containment Level 2 (CL2);• 10+ years’ experience in excellent analytical, organizational, and project management skills and data analysis;• 10+ years’ experience in the grant application, project implementation, and mentoring students;• Self-motivated to work on multiple projects independently;• Active learning and implementing novel scientific concepts and innovations into grant application and project fulfillment; • Thinking out of the box for problem-solving;• Strong collaboration skills with clinicians, pathologists in histology and cytology, and scientists on cross-departmental/disciplinary team projects;• Demonstrate oral and written communication skills, good interpersonal skills;• Excellent technical skills and extensive experience with MS Office, Endnote, etc..AREAS OF EXPERTISE• Molecular & Cell Biology (cell culture, cell-based assay, western blot, immunoprecipitation, fluorescence microscopy, flow cytometry, DNA&RNA isolation, microRNA analysis, RT-qPCR, digital PCR);• Cancer research (oral tumor organoids, target discovery and validation, and animal model characterization);• Clinical medicine (patient specimen-based histology, immunohistochemistry diagnostic assays, multiplex immunofluorescence, digital pathology, and quantitative image analysis);• Tumor genetics and molecular diagnostics (Identification of miRNAs, mRNAs, and DNA mutants in clinical biopsies via ultra-high-throughput next-generation sequencing (NGS), real-time qPCR and digital PCR, and clinical biomarker assay development).